Nabriva Therapeutics plc Quarterly Depreciation, Depletion and Amortization in USD from Q1 2016 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
Nabriva Therapeutics plc quarterly/annual Depreciation, Depletion and Amortization history and growth rate from Q1 2016 to Q1 2023.
  • Nabriva Therapeutics plc Depreciation, Depletion and Amortization for the quarter ending March 31, 2023 was $21K, a 73.1% decline year-over-year.
  • Nabriva Therapeutics plc annual Depreciation, Depletion and Amortization for 2022 was $217K, a 39% decline from 2021.
  • Nabriva Therapeutics plc annual Depreciation, Depletion and Amortization for 2021 was $356K, a 14.6% decline from 2020.
  • Nabriva Therapeutics plc annual Depreciation, Depletion and Amortization for 2020 was $417K, a 5.3% increase from 2019.
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $21K -$57K -73.1% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-22
Q1 2022 $78K -$21K -21.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q1 2021 $99K -$4K -3.88% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $103K -$22K -17.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 $125K -$8K -6.02% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 $133K +$57K +75% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-10
Q1 2017 $76K +$31K +68.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q1 2016 $45K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.